1 2 Following this program, what percentage of your patients with AML do you plan to test for FLT3-ITD upon initial evaluation? * < 10% 10–25% 25–50% 50–75% > 75% N/A: not applicable to my healthcare role Following this program, what percentage of your patients with AML do you plan to test for IDH1 and 2 mutations upon initial evaluation? * < 10% 10–25% 25–50% 50–75% > 75% N/A: not applicable to my healthcare role To what extent are you motivated to improve the collaboration and communication between the oncologist and pathologist in your center? * Very unmotivated Somewhat unmotivated Neutral Somewhat motivated Very motivated Which of the following emerging therapies do you anticipate will have the greatest impact on your clinical management of patients with AML? * Novel chemotherapeutic agents New hypomethylating agents Antibody-drug conjugates BCL-2 inhibitors FLT3 inhibitors IDH inhibitors Leave this field blank
